Solid Biosciences Inc.
www.solidbio.com
Latest From Solid Biosciences Inc.
Made In China Gene Therapy A Father's Quest To Save Son With UltraRare Condition
Patient-driven drug development meets the old saying of "where there's a will, there's a way" in China, potentially the world's largest market for rare disease treatments.
Finance Watch: Amarin Raises Cash To Boost Vascepa Marketing Under Soon-To-Be Expanded Label
Public Company Edition: Two months before the deadline for the company's sNDA, the US FDA has not indicated it will hold an advisory committee meeting for the triglyceride-lowering drug. Also, Seattle Genetics raises $575m, Atara and Ra bring in $150m each and Cara completes $145.5m offering.
Sarepta Shares Bounce As Pfizer’s DMD Gene Therapy Sparks Safety Concerns
Pfizer is forging ahead with a Phase III trial for its DMD therapy, even though Phase Ib data raised safety worries. Gene therapy rival Sarepta’s shares were up by 17% on the news.
Finance Watch: Tetraphase Reorganization Follows Troubled Antibiotic Commercialization Path
Tetraphase's plan to downsize may put the company on the same path as now-bankrupt Achaogen. Also, Bain raises $900m for its second life science fund, Provention calls off post-ADA offering and Oncologie raises $80m series B.
Company Information
- Industry
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Alias(es)
- Solid Ventures
- Solid Biosciences LLC
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Solid Biosciences Inc.
- Senior Management
-
Ilan Ganot, CEO
Jennifer Ziolkowski, CFO
Carl Morris , PhD, CSO
Joel Schneider, PhD, CTO, Head, Exploratory R&D
Jorge A Quiroz, MD, CMO
Alvaro Amorrortu, COO - Contact Info
-
Solid Biosciences Inc.
Phone: (617) 337-4680
161 First St.
3rd Floor
Cambridge, MA 02142
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice